Hall Alistair S, Strauss Martin H
Heart. 2007 Sep;93(9):1011-4. doi: 10.1136/hrt.2006.107185.
"Logic dictates that angiotensin converting enzyme inhibitors should remain the preferred drug across the entire spectrum of cardiometabolic disease"
从逻辑上讲,血管紧张素转换酶抑制剂在整个心脏代谢疾病谱中都应仍是首选药物。